Funding cuts in medical research have emerged as a prominent concern, particularly as recent reductions threaten critical NIH funding essential for groundbreaking studies.The halt in resources not only disrupts the flow of scientific inquiry but also jeopardizes the rigorous IRB oversight needed to protect medical research safety across diverse clinical trials.